Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 2Phase 2/3 1Phase 1 1

Status

Recruiting 4Active not recruiting 4

Sponsor Class

OTHER 25INDUSTRY 8NIH 3NETWORK 1

Study Type

Interventional 8

Sponsor

Cancer Type

Gastrointestinal 8Thoracic 1

Conditions

Melanoma 8Carcinoma, Non-Small-Cell Lung 8Carcinoma, Hepatocellular 8Squamous Cell Carcinoma of Head and Neck 6Small Cell Lung Carcinoma 5Neoplasms 4Lung Neoplasms 4Prostatic Neoplasms 3Diabetes Mellitus, Insulin-Dependent, 12 3Colorectal Neoplasms 3Carcinoma, Renal Cell 3Advanced Solid Tumors 3Urinary Bladder Neoplasms 2Recurrence 2Lymphoma, Large B-Cell, Diffuse 2Liver Neoplasms 2Head and Neck Neoplasms 2Biliary Tract Neoplasms 2Urothelial Cancer 1Unresectable Hepatocellular Carcinoma 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Solid Tumor 1Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma 1Peritoneal Neoplasms 1Part A and B: Advanced Solid Malignancies 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Non Small Cell Lung Cancer NSCLC 1Non - Small Cell Lung Cancer NSCLC 1

Interventions

Sorafenib 79pembrolizumab 37Bevacizumab 36Nivolumab 33lenvatinib 30atezolizumab 24durvalumab 17Oxaliplatin 12Ipilimumab 12regorafenib 9Capecitabine 9tremelimumab 8Injections 8Doxorubicin 8tislelizumab 7sintilimab 7Fluorouracil 7cabozantinib 6budigalimab 6brivanib 6Ramucirumab 6toripalimab 5Gemcitabine 5Everolimus 5Cyclophosphamide 5ADI PEG20 5fludarabine 4Sunitinib 4Leucovorin 4E-7386 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

8 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Hepatocellular × tremelimumab × Clear all
NCT02519348 2026-06-03

A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma

MedImmune LLC

Phase 2 Active not recruiting
433 enrolled 26 charts
Gastrointestinal

Carcinoma, Hepatocellular

NCT07391670 2026-05-15

IMFINZI-subQ

AstraZeneca

Phase 1 Recruiting
40 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Small Cell Lung Carcinoma

NCT07081633 2026-05-12

TREMENDOUS-2

AstraZeneca

Phase 2 Active not recruiting
114 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT06921785 2026-05-11

ARTEMIDE-HCC01

AstraZeneca

Phase 3 Recruiting
1,220 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT05301842 2026-04-07

EMERALD-3

AstraZeneca

Phase 3 Active not recruiting
760 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT03298451 2026-03-20

HIMALAYA

AstraZeneca

Phase 3 Active not recruiting
1,324 enrolled 31 charts 1 FDA
Gastrointestinal

Carcinoma, Hepatocellular

NCT06109272 2025-08-15

LIVIGNO-2

AbbVie

Phase 2/3 Recruiting
660 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT05557838 2025-02-07

TREMENDOUS

AstraZeneca

Phase 3 Recruiting
210 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡